| Type 2 Diabetes Mellitus |
1 |
1 |
| DPP-4 Inhibitors |
0 |
0.73 |
| GLP-1 Receptor Agonist |
0 |
0.99 |
| Receptors |
0 |
0.41 |
| Spondylitis, Spondylosis, Kyphosis |
0 |
0.32 |
| Canada |
0 |
0.31 |
| Rheumatoid Arthritis |
0 |
0.28 |
| Cerebrovascular Accident |
0 |
0.26 |
| Arthritis |
0 |
0.21 |
| Infarction |
0 |
0.21 |
| Thromboembolism |
0 |
0.21 |
| Myocardial Infarction (MI) |
0 |
0.19 |
| Ankylosing Spondylitis |
0 |
0.1 |
| Artificial Intelligence |
0 |
0.1 |
| Axial spondyloarthritis |
0 |
0.1 |
| Board Certification |
0 |
0.1 |
| Grant |
0 |
0.1 |
| Healthcare and Medical Technology |
0 |
0.1 |
| Inflammatory Bowel Disease |
0 |
0.1 |
| Ischemic Stroke |
0 |
0.1 |
| Obesity |
0 |
0.1 |
| Rheumatic Disease |
0 |
0.1 |